New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
10:01 EDTMTGE, VOD, VOXX, URBN, TOT, STO, SWN, O, PHMD, LFL, ITC, HII, CXP, BMY, BEAV, AAUKY, WACOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Capital Mortgage (MTGE) downgraded to Market Perform at JMP Securities... Anglo American (AAUKY) downgraded to Neutral from Outperform at Credit Suisse... BE Aerospace (BEAV) downgraded to Neutral from Buy at UBS... Bristol-Myers (BMY) downgraded at BMO Capital... Columbia Property Trust (CXP) downgraded to Equal Weight from Overweight at Morgan Stanley... Huntington Ingalls (HII) downgraded at BofA/Merrill... ITC Holdings (ITC) downgraded to Neutral from Overweight at JPMorgan... LATAM Airlines (LFL) downgraded to Market Perform from Outperform at Raymond James... PhotoMedex (PHMD) downgraded to Hold from Buy at Ascendiant... Realty Income (O) downgraded to Neutral from Buy at Ladenburg... Southwestern Energy (SWN) downgraded to Neutral from Conviction Buy at Goldman... Statoil (STO) downgraded to Sector Perform from Top Pick at RBC Capital... Total (TOT) downgraded to Sector Perform from Outperform at RBC Capital... Urban Outfitters (URBN) downgraded to Market Perform from Outperform at FBR Capital... VOXX International (VOXX) downgraded to Neutral from Buy at B. Riley... Vodafone (VOD) downgraded to Neutral from Buy at Goldman... Walter Investment (WAC) downgraded to Sell from Neutral at Compass Point.
News For MTGE;AAUKY;BEAV;BMY;CXP;HII;ITC;LFL;PHMD;O;SWN;STO;TOT;URBN;VOXX;VOD;WAC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
October 14, 2014
13:11 EDTTOTTotal moving ahead with 60% expansion of Joslyn project, Financial Post says
Subscribe for More Information
12:39 EDTBEAVMonmouth Real Estate acquires industrial building for $5.2M
Subscribe for More Information
11:23 EDTBMYBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
09:04 EDTSTOStatoil, Exxon Mobil announce additional discovery offshore Tanzania
Statoil (STO) and co-venturer Exxon Mobil (XOM) announced that the Giligiliani-1 exploration well has resulted in a new natural gas discovery offshore Tanzania. The discovery of an additional 1.2 trillion cubic feet of natural gas in place in the Giligiliani-1 well brings the total of in-place volumes up to approximately 21 tcf in block 2. The Giligiliani-1 discovery is the venture’s seventh discovery in block 2. Statoil operates the licence on block 2 on behalf of Tanzania Petroleum Development Corporation and has a 65% working interest. ExxonMobil Exploration and Production Tanzania Limited holds the remaining 35%.
05:23 EDTVODVodafone initiated with a Buy at Deutsche Bank
Subscribe for More Information
October 13, 2014
10:08 EDTAAUKYOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:08 EDTVOXXOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Bankrate (RATE) downgraded to Equal Weight from Overweight at Stephens... CME Group (CME) downgraded to Market Perform from Outperform at Wells Fargo... Cliffs Natural (CLF) downgraded to Neutral from Overweight at JPMorgan... Dana Holding (DAN) downgraded to Sector Perform from Outperform at RBC Capital... Darden (DRI) downgraded to Neutral from Overweight at Piper Jaffray... Dover (DOV) downgraded to Neutral at RW Baird... DryShips (DRYS) downgraded to Underperform from Outperform at Imperial Capital... Infineon (IFNNY) downgraded to Neutral from Overweight at JPMorgan... J.C. Penney (JCP) downgraded to Sell from Neutral at UBS... Johnson Controls (JCI) downgraded to Outperform from Top Pick at RBC Capital... Juniper (JNPR) downgraded to Hold from Buy at Argus... Kennametal (KMT) downgraded to Market Perform from Outperform at Wells Fargo... Masco (MAS) downgraded to Equal Weight from Overweight at Barclays... New Gold (NGD) downgraded to Neutral from Overweight at JPMorgan... ON Semiconductor (ONNN) downgraded to Sector Perform from Outperform at Pacific Crest... PBF Energy (PBF) downgraded to Underweight from Equal Weight at Barclays... Parker-Hannifin (PH) downgraded to Market Perform from Outperform at Wells Fargo... STMicroelectronics (STM) downgraded to Neutral from Overweight at JPMorgan... Silicon Laboratories (SLAB) downgraded to Sector Perform at Pacific Crest... VOXX International (VOXX) downgraded to Market Perform from Outperform at Cowen.
10:08 EDTVOXX, AAUKYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:37 EDTVOXXFollow-up: VOXX International upgraded at Craig-Hallum
As previously reported, Craig-Hallum upgraded VOXX International to Buy from Hold The firm upgraded shares based on valuation and maintained its $10 price target.
08:46 EDTAAUKYAnglo American initiated with a Buy at Canaccord
Subscribe for More Information
08:05 EDTBMYBristol-Myers, Pharmacyclics, Janssen announce clinical collaboration
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), and Janssen Research & Development, LLC (JNJ) announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. Bristol-Myers Squibb has proposed the name OPDIVO, which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies. The study will be conducted by Janssen. Additional details of the collaboration were not disclosed.
07:48 EDTVOXXVOXX International downgraded to Market Perform from Outperform at Cowen
Subscribe for More Information
07:31 EDTVOXXVOXX International upgraded to Buy from Hold at Craig-Hallum
Subscribe for More Information
07:13 EDTBMYBioFlorida to hold a conference
Subscribe for More Information
06:36 EDTTOTSaudi Arabia content to let oil prices stay low, Reuters reports
Subscribe for More Information
05:24 EDTAAUKYAnglo American upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
05:18 EDTSTOStatoil sells 15.5% share in Shah Deniz to PETRONAS for $2.2B
Statoil has sold its 15.5% participating interest in the Shah Deniz production sharing agreement, 15.5% share in the South Caucasus Pipeline Company, or SCPC, 15.5% share in the SCPC holding company, and 12.4% share in the Azerbaijan Gas Supply Company, or AGSC, to the Malaysian oil and gas company PETRONAS. The transaction value is $2.25B. Statoil's Q2 production from the Shah Deniz field was 38,000 barrels of oil equivalent per day. The effective date is January 1. The transaction is expected to be closed early 2015, subject to approval from the relevant authorities.
05:16 EDTSTOStatoil sells 15.5% share in Shah Deniz to PETRONAS for $2.2B
Subscribe for More Information
October 12, 2014
13:53 EDTTOTKuwaiti Minister says OPEC unlikely to cut production, WSJ says
Subscribe for More Information
13:45 EDTTOTSaudis take aggressive oil measures in Europe, WSJ says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use